11:00 AM EST, 12/22/2025 (MT Newswires) -- Dogwood Therapeutics ( DWTX ) said Monday that an interim analysis of its Phase 2b study for Halneuron showed the treatment is effectively reducing pain in patients suffering from chemotherapy-induced neuropathic pain.

The company said an independent statistical review committee examined unblinded data from 97 patients who completed treatment in the four-week trial and found separation from placebo on pain reduction. The study is evaluating Halneuron in patients with long-standing chemotherapy-induced neuropathic pain, or CINP.

Dogwood said it continues to expect top-line results from the trial in Q3 of 2026, citing current enrollment trends and the interim findings. The company said projected enrollment should provide statistical power of roughly 80% to 85% to detect a treatment difference.

Patients included in the interim analysis had an average CINP duration of about five years, and 67% were receiving stable doses of other chronic pain medications, the company said, adding that the overall study dropout rate of about 4.4% was well below levels typically seen with approved chronic pain therapies.

The company said the interim results, while the study remains blinded, support the safety and tolerability profile for Halneuron observed in earlier clinical trials.

Shares of the company were down nearly 15% in recent Monday trading.

Price: 5.49, Change: -0.97, Percent Change: -14.96